Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner

PloS One
Mohammed A SamadPeter M Kang

Abstract

Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a good predictor of clinical outcome. Selective endothelin A (ETA) receptor antagonist used with renin-angiotensin system (RAS) inhibitors prevents development of proteinuria in CKD. However, whether the improvement in proteinuria would have beneficial effects on CVD, independent of RAS inhibition, is not well understood. In this study, we investigated whether atrasentan, an ETA receptor antagonist, has renal and cardiovascular effects independent of RAS inhibition. Male Dahl salt sensitive (DSS) rats, at six weeks of age, received water with or without different doses of atrasentan and/or enalapril under high salt (HS) diet or normal diet (ND) for 6 weeks. At the end of 12th week, atrasentan at a moderate dose significantly attenuated proteinuria and serum creatinine without reducing mean arterial pressure (MAP), thereby preventing cardiac hypertrophy and improving cardiac function. ACE inhibitor enalapril at a dose that did not significantly lowered BP, attenuated cardiac hypertrophy while moderately improving cardiac function without reducing proteinuria and serum creatinine level. Nonetheless, combined therapy of atrasentan and e...Continue Reading

References

Aug 5, 1991·FEBS Letters·K HosodaH Imura
Aug 1, 1989·Kidney International·J S SilberbergA D Sniderman
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A InoueT Masaki
Jul 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P S ParfreyP E Barre
Mar 24, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K DemuthG M London
Aug 15, 1998·Journal of Human Hypertension·T SakaiK Arakawa
Mar 19, 1999·European Journal of Pharmacology·J R Wu-WongT J Opgenorth
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·R M Kedzierski, M Yanagisawa
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Oct 3, 2002·Circulation·Hans L HillegeUNKNOWN Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
Nov 15, 2002·Journal of Molecular and Cellular Cardiology·Jasmina Varagic, Edward D Frohlich
Jun 5, 2003·Journal of Hypertension·Ming YuRichard J Roman
Jul 25, 2003·Journal of Molecular and Cellular Cardiology·Peter H Sugden
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Nov 5, 2003·Circulation·Stuart Rich, Vallerie V McLaughlin
Nov 8, 2003·Hypertension·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Mar 6, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Peter M KangSeigo Izumo
Apr 22, 2004·Journal of the American Society of Nephrology : JASN·Daniel E WeinerMark J Sarnak
Jun 15, 2004·Journal of the American College of Cardiology·Richard N ChannickLewis J Rubin
Aug 18, 2004·Journal of Hypertension·Toshio NishikimiHiroaki Matsuoka
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Jan 25, 2005·Lancet·A Meguid El Nahas, Aminu K Bello
Feb 5, 2005·American Journal of Hypertension·Atsuhisa SatoTakao Saruta
Sep 10, 2005·British Journal of Pharmacology·Anthony AllanLindsay Brown
Dec 1, 2005·Kidney International·Meguid El Nahas
Nov 4, 2006·Journal of the American Society of Nephrology : JASN·Alejandro R ChadeLilach O Lerman

❮ Previous
Next ❯

Methods Mentioned

BETA
enzymatic dissociation
protein assay

Software Mentioned

PowerLab
GraphPad Prism

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.